Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.53
-2.99 (-23.92%)
At close: Jul 24, 2026, 4:00 PM EDT
9.53
0.00 (0.05%)
After-hours: Jul 24, 2026, 7:45 PM EDT

Zevra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
122.29106.4723.6127.4610.4628.65
Revenue Growth
201.29%350.92%-14.02%162.58%-63.50%115.61%
Gross Profit
105.2689.9916.225.2910.1226.59
Operating Income
4.14-62.94-87-49.6-42.517.73
Net Income
74.1683.23-105.51-46.05-41.54-62.9
Earnings Per Share
1.991.35-2.28-1.30-0.78-2.11
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
200.62191.0169.567.7482.85112.35
Total Debt
1.1563.2160.343.7714.121.59
Net Cash (Debt)
199.47127.819.223.9768.72110.76
Net Cash Growth
25022.04%1289.18%-61.62%-65.12%-37.95%-
Net Cash Per Share
3.452.230.200.681.993.72

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
12.77-1.6-69.67-33.54-18.7210.44
Capital Expenditures
-0.77-0.84--0.3-0.09-0.1
Free Cash Flow
12-2.43-69.67-33.83-18.8110.34
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
86.07%84.52%68.59%92.09%96.72%92.81%
Operating Margin
3.39%-59.12%-368.47%-180.63%-406.44%26.98%
Pretax Margin
62.09%81.41%-381.76%-167.69%-404.75%-29.74%
Profit Margin
60.65%78.17%-446.85%-167.69%-397.24%-29.86%
FCF Margin
9.81%-2.29%-295.04%-123.20%-179.86%36.08%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
4.806.64----
Forward PE
16.7419.15102.50102.50102.5024.17
P/FCF Ratio
46.94----29.50
PS Ratio
4.604.7818.969.9115.1610.64